Medicale Corp. Files 10-Q for June 2025 Quarter

TL;DR

Medicale Corp. 10-Q filed for June 30, 2025. Financials are in.

AI Summary

Medicale Corp. filed its 10-Q for the period ending June 30, 2025. The company, incorporated in Nevada, operates in the health services sector. Its principal executive offices are located in Wellington, Florida. The filing covers financial information for the quarter and year-to-date periods.

Why It Matters

This filing provides investors with the latest financial performance and operational details of Medicale Corp., crucial for understanding its current health and future prospects.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new information presented in the header.

Key Numbers

• 20250630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
• 20250815 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Medicale Corp. (company) — Filer
• 9314 FOREST HILL BLVD #929, WELLINGTON, FL 33411 (location) — Business and Mail Address
• NV (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.01 — verted to the Company's common stock at $0.01 per share. As of June 30, 2025, the acc
• $0.04 — verted to the Company's common stock at $0.04 per share. As of June 30, 2025, the acc
• $0.15 — verted to the Company's common stock at $0.15 per share. As of June 30, 2025, the acc
• $5,528 — he three months ended June 30, 2025 was $5,528 compared with net loss of $10,461 for t
• $10,461 — 25 was $5,528 compared with net loss of $10,461 for the three months ended June 30, 202
• $30,483 — the nine months ended June 30, 2025 was $30,483 compared with net loss of $41,332 for t
• $41,332 — 5 was $30,483 compared with net loss of $41,332 for the nine months ended June 30, 2024
• $0 — ember 30, 2024, our Company had cash of $0 and $159, respectively. As at June 30,
• $159 — 0, 2024, our Company had cash of $0 and $159, respectively. As at June 30, 2025, ou
• $29,439 — our Company had current liabilities of $29,439 as compared to $15,507 as of September
• $15,507 — t liabilities of $29,439 as compared to $15,507 as of September 30, 2024. The increase
• $15,348 — pared with a working capital deficit of $15,348 as at September 30, 2024. The increase

Filing Documents

• medicale_i10q-063025.htm (10-Q) — 332KB
• medicale_ex3101.htm (EX-31.1) — 11KB
• medicale_ex3201.htm (EX-32.1) — 5KB
• 0001683168-25-006213.txt ( ) — 1883KB
• mcle-20250630.xsd (EX-101.SCH) — 15KB
• mcle-20250630_cal.xml (EX-101.CAL) — 21KB
• mcle-20250630_def.xml (EX-101.DEF) — 32KB
• mcle-20250630_lab.xml (EX-101.LAB) — 159KB
• mcle-20250630_pre.xml (EX-101.PRE) — 124KB
• medicale_i10q-063025_htm.xml (XML) — 168KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Condensed Financial Statements 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 16 Item 4.

Controls and Procedures

Controls and Procedures 16

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 18 Item 1A.

Risk Factors

Risk Factors 18 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 18 Item 3. Defaults Upon Senior Securities 18 Item 4. Mine Safety Disclosures 18 Item 5. Other Information 18 Item 6. Exhibits 18

SIGNATURES

SIGNATURES 19 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking "intends", "estimates", "plans" and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Forward-looking statements are based on our current

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking and regulatory conditions. A description of these and other risks and uncertainties that could affect our business appears in the section captioned "Risk Factors" in our Annual Report on Form 10-K which we filed with the Securities and Exchange Commission ("SEC") on August 19, 2024 (the "Form 10-K"). The risks and uncertainties described under "Risk Factors" are not exhaustive. Given these uncertainties, readers of this Quarterly Report on Form 10-Q ("Quarterly Report") are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments. 3

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS MEDICALE CORP. CONDENSED BALANCE SHEETS (Unaudited) June 30, September 30, 2025 2024 ASSETS Current Assets Cash $ – $ 159 Total Current Assets – 159 Total Assets $ – $ 159 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued liabilities $ 8,447 $ – Accrued interest payable 8,992 3,507 Current liabilities from discontinued operations 12,000 12,000 Total Current Liabilities 29,439 15,507 Non-current convertible note payable 99,977 83,585 Total Long-term Liabilities 99,977 83,585 Total Liabilities 129,416 99,092 STOCKHOLDERS' DEFICIT Common Stock: $ 0.0001 par value, 75,000,000 shares authorized, 5,920,000 shares issued and outstanding 592 592 Additional paid-in capital 76,320 76,320 Accumulated deficit ( 206,328 ) ( 175,845 ) Total Stockholders' Deficit ( 129,416 ) ( 98,933 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ – $ 159 The accompanying notes are an integral part of these unaudited condensed financial statements. 4 MEDICALE CORP. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended For the Nine Months Ended June 30, June 30, June 30, June 30, 2025 2024 2025 2024 Operating Expenses General and administration $ 3,575 $ 9,288 $ 24,839 $ 39,198 Total operating expenses 3,575 9,288 24,839 39,198 Net loss from operations ( 3,575 ) ( 9,288 ) ( 24,839 ) ( 39,198 ) Other expense Other expense – – ( 159 ) – Interest expense ( 1,953 ) ( 1,173 ) ( 5,485 ) ( 2,134 ) Total other expense ( 1,953 ) ( 1,173 ) ( 5,644 ) ( 2,134 ) Net loss before taxes ( 5,528 ) ( 10,461 ) ( 30,483 ) ( 41,332 ) Provision for income taxes – – – – Net loss $ ( 5,528 ) $ ( 10,461 ) $ ( 30,483 ) $ ( 41,332 ) Net Loss Per Common Share – Basic and Diluted $ ( 0.00 ) $ ( 0.00 ) $ ( 0.01 ) $ ( 0.01 ) Weighted Average Common Shares Outstanding 5,920,000

financial statements or disclosures upon adoption

financial statements or disclosures upon adoption. Recent Adopted Accounting Standards In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.The adoption of ASU 2023-07 has not had a material effect on the Company's statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures ("ASU 2023-09"), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of ASU 2023-09 has not had a material effect on the Company's financial statements and disclosures. 10 Note 4– COMMON STOCK The Company has 75,000,000 , $ 0.0001 par value shares of voting common stock authorized. All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. As of June 30, 2025 and September 30, 2024, the Company had 5,920,000 shares issued and outstanding, respectively. Voting Common Stock All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

MANAGEMENT'S DISCUSSION AND ANALYSIS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward-Looking Statements

Forward-Looking Statements This quarterly report contains forward-looking "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report. In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all reference

View Full Filing

View this 10-Q filing on SEC EDGAR